Related Experiment Video
Updated: Mar 3, 2026

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
Published on: November 11, 2025
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome
Jitendra A Sattigeri1, Sachin Sethi1, Joseph A Davis1
1New Drug Discovery Research, R&D III, Ranbaxy Laboratories Limited, Plot 20, Sector 18, Udyog Vihar, Gurgaon, Haryana 122015, India.
Abstract:
Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Cholesterol: Significance and Regulation
Considering cholesterol and...

